Home › Funds › Orbis Allan Gray Ltd › CRSP
Orbis Allan Gray Ltd position in CRSP
CRISPR THERAPEUTICS AG · Health Care
Orbis Allan Gray Ltd reported holding 4,519,261 shares of CRSP (CRISPR THERAPEUTICS AG) in its Q3 2026 13F filing — a position valued at US$250.0M, representing 0.83% of its reported portfolio and ranking #40 among its reported holdings. Orbis Allan Gray Ltd has disclosed CRSP holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Orbis Allan Gray Ltd's CRSP position evolved
Orbis Allan Gray Ltd first disclosed a stake in CRSP in Q4 2024 at 1,476,119 shares (US$58.1M). The position peaked in Q3 2025 at 4,982,085 shares, worth US$322.9M. Across 8 filings, Orbis Allan Gray Ltd increased the stake 5 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 4,519,261 shares valued at US$250.0M — a reduction of -929,900 shares quarter over quarter.. Notable position changes include a 77% increase in Q2 2025 (shares rose 32% over the following quarter), a 80% increase in Q3 2025 (shares fell 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 1.48M | $58.10M | New |
| Q1 2025 | 1.56M | $53.19M | Add |
| Q2 2025 | 2.76M | $134.47M | Add |
| Q3 2025 | 4.98M | $322.89M | Add |
| Q4 2025 | 5.95M | $312.03M | Add |
| Q1 2026 | 6.11M | $290.46M | Add |
| Q2 2026 | 5.45M | $297.20M | Reduce |
| Q3 2026 | 4.52M | $250.01M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CRSP and 13F data
CRSP (CRISPR THERAPEUTICS AG) is a Health Care company. 29 other funds we track also report a position in CRSP — the largest reported positions include ARK Invest (US$556.3M), GSK plc (US$144.3M), SR ONE CAPITAL MANAGEMENT, LP (US$111.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CRSP
- ARK Invest 10.06M sh · $556.34M · Q3 2026
- GSK plc 2.61M sh · $144.30M · Q3 2026
- SR ONE CAPITAL MANAGEMENT, LP 2.04M sh · $111.19M · Q2 2026
- Amova Asset Management Americas, Inc. 1.45M sh · $80.36M · Q3 2026
- EcoR1 Capital, LLC 1.39M sh · $76.85M · Q3 2026
- NEA Management Company, LLC 1.06M sh · $57.73M · Q2 2026
More on Orbis Allan Gray Ltd
FAQ
How long has Orbis Allan Gray Ltd held CRSP?
Orbis Allan Gray Ltd has disclosed CRSP holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is Orbis Allan Gray Ltd's current position in CRSP?
As of Q3 2026, Orbis Allan Gray Ltd holds 4.52M shares of CRSP (CRISPR THERAPEUTICS AG), valued at $250.01M, representing 0.83% of its reported portfolio and ranking #40.
Has Orbis Allan Gray Ltd been buying or selling CRSP?
In the latest 13F filing (Q3 2026), Orbis Allan Gray Ltd reduced its position in CRSP. The position peaked in Q3 2025 at 4.98M shares.
Which other funds hold CRSP?
Other major institutional holders of CRSP include ARK Invest, GSK plc, SR ONE CAPITAL MANAGEMENT, LP, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.